ImmunoBiochem

ImmunoBiochem is on a mission to develop novel bioconjugate therapeutics, such ADCs, ISACs and DACs, to address significant unmet need in oncology, immuno-oncology and immunology. In precision oncology and immuno-oncology, ImmunoBiochem focuses on the discovery of novel tumor secretome-based targets utilizing a combination of high-throughput functional assays, mass spectrometry and AI/ML to unravel unique cancer biology. In precision immunology, ImmunoBiochem’s novel bioconjugates utilize unique antibody targets for the delivery of potent protein degrader payloads modulating select immunological pathways in specific cell subtypes in the desirable context in relevant autoimmune disorders, avoiding broad side-effects of existing biologics and small molecule therapeutics.